5463-29-6

Usage

Uses

Used in Pharmaceutical Industry:
6-BROMO-2-HYDROXYQUINOLINE-4-CARBOXYLIC ACID is used as an antibacterial agent for its potential to combat bacterial infections. Its unique chemical structure allows it to target and inhibit bacterial growth, making it a valuable asset in the development of new antibiotics.
Used in Medicinal Chemistry Research:
6-BROMO-2-HYDROXYQUINOLINE-4-CARBOXYLIC ACID serves as a building block for the synthesis of biologically active compounds. Its presence in various chemical reactions can lead to the creation of new molecules with therapeutic potential, contributing to the advancement of drug discovery and design.
Used in Drug Discovery and Design:
6-BROMO-2-HYDROXYQUINOLINE-4-CARBOXYLIC ACID is utilized as a key component in the development of novel drugs. Its unique properties and reactivity make it an ideal candidate for further research and exploration, with the aim of discovering new therapeutic agents to address various medical conditions.

InChI:InChI=1/C10H6BrNO3/c11-5-1-2-8-6(3-5)7(10(14)15)4-9(13)12-8/h1-4H,(H,12,13)(H,14,15)

Upstream product

• 141-82-2 malonic acid 
• 87-48-9 5-Bromo-1H-indole-2,3-dione 
• 541-50-4 2-acetoacetic acid 
• 89446-19-5 6-bromo-4-methyl-quinolin-2-ol 
• 38418-24-5 N-(4-bromophenyl)-3-oxobutyramide 
• 91-56-5 indole-2,3-dione 

Downstream Products

• 1549775-76-9 2-hydroxy-6-phenyl-N-(pyridin-3-yl)quinoline-4-carboxamide 
• 1549775-81-6 2-chloro-6-phenyl-N-(pyridin-3-yl)quinoline-4-carboxamide 
• 1549772-61-3 2-(5-methylfuran-2-yl)-6-phenyl-N-(pyridin-3-yl)quinoline-4-carboxamide 
• 287176-62-9 6-bromo-2-chloro-4-quinolinecarboxylic acid 
• 286430-90-8 6-bromo-2-chloroquinoline-4-carbonitrile 

Relevant academic research and scientific papers

INHIBITORS OF SARM1

The present disclosure provides compounds and methods useful for inhibiting SARM1 and/or treating and/or preventing axonal degeneration.

Discovery, synthesis and molecular substantiation of N-(benzo[d]thiazol-2-yl)-2-hydroxyquinoline-4-carboxamides as anticancer agents

The effort was taken to develop a series of benzothiazole and quinoline fused bioactive compounds obtained through a four-step synthetic route using a range of substituted acetoacetanilides. Achieved N-(benzo[d]thiazol-2-yl)-2-hydroxyquinoline-4-carboxamides (6a-l) were produced up to 96% of yield while the eco-friendly p-TSA used as a catalyst. Further, the anticancer activity of these compounds was determined using a range of cancer cell lines starting from MCF-7 (Breast cancer), HCT-116 (Colon cancer), PC-3 & LNCaP (Prostate) and SK-HEP-1 (Liver cancer). Present study compounds were also testified for antioxidant properties prior to anticancer studies since the Reactive Oxygen Species (ROS) being vital in cancer development. To determine the cell membrane stability effects of the compounds, human red blood cells (HRBC) based membrane protection assay was determined. In the results, compounds 6a-l were able to produce a dominated result values over PC3 cell lines (Prostate cancer) than the other cell lines used in this study. Since the connectivity of human germ cell alkaline phosphatase (hGC-ALP) in the development of prostate cancer is known, the most active compounds were evaluated for the hGC-ALP inhibition in order to ensure a mechanism of anticancer action of these compounds. The mode of interaction and binding affinity of these compounds was also investigated by a molecular docking study. In the results, 6d, 6i, 6k, and 6l were found with least IC50 values 0.075 μM and highest relative activity of 92%, 90%, and 96% respectively. The need for further animal model evaluation and pre-clinical studies recognized.

COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES

The present invention relates to a compositions for and methods of cancer treatment in which compounds of Formula I or Formula II. In some aspects, the treatment of B-cell Lymphoma or other hematopoietic cancers is encompassed. In other aspects, the invention provides methods for treating particular types of hematopoietic cancers, such as B-cell lymphoma, using a combination of one or more compounds of Formula I or Formula II. Combination therapy with, for example, a class of therapeutics known as 26S proteasome inhibitors, for example, Bortezomib, are also included. In another aspect the present invention relates to autoimmune treatment with compounds of Formula I or Formula II. In another aspect, this invention relates to methods for identifying compounds, for example, compounds of the BH3 mimic class, that have unique in vitro properties that predict in vivo efficacy against B-cell lymphoma tumors and other cancers as well as autoimmune disease.